Human leucocytary interferon (IFN) in a concentration of 2,000 Ul/ml stops the development of 9 Rhinovirus (RV) strains. The use of serum IFN antibodies (SAIF) reverses this effect. Of 256 nasal aspirates culture negative for other respiratory viruses, 40 RV were isolated with SAIF as opposed to 19 without serum anti IFN. The frequency and some clinical aspects are emphasized in infants: 43% had bronchiolitis similar to respiratory syncytial virus (RSV) infections and atopy was frequent.
Download full-text PDF |
Source |
---|
Ital J Pediatr
January 2025
Department of Neonatology, Children's Hospital, Capital Institute of Pediatrics, Beijing, 100020, China.
Background: To explore the effect of non-pharmacological interventions (NPIs) on respiratory pathogen profiles among hospitalized infants aged 0-3 months in Beijing during the coronavirus disease 2019 (COVID-19) pandemic.
Methods: Respiratory specimens were collected from 1,184 infants aged 0-3 months who were hospitalized for acute respiratory infection at the Children's Hospital affiliated with the Capital Institute of Pediatrics from January 2018 to December 2023. The data were divided into three groups-the pre-epidemic (January 2018 to December 2019), epidemic prevention and control (January 2020 to December 2022), and post-epidemic (January 2023 to December 2023) groups-based on the outbreak of COVID-19 and the implementation and termination of NPIs.
PLoS One
January 2025
Sydney Medical School, University of Sydney, Sydney, New South Wales (NSW), Australia.
Acute respiratory infections cause significant paediatric morbidity, but for pathogens other than influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, systematic monitoring is not commonly performed. This retrospective analysis of six years of routinely collected respiratory pathogen multiplex PCR testing at a major paediatric hospital in New South Wales Australia, describes the epidemiology, year-round seasonality, and co-detection patterns of 15 viral respiratory pathogens. 32,599 respiratory samples from children aged under 16 years were analysed.
View Article and Find Full Text PDFRespirology
January 2025
School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
Background And Objective: Asthma-COPD overlap (ACO) is characterized by patients exhibiting features of both asthma and COPD. Currently, there is no specific treatment for ACO. This study aimed to investigate the therapeutic potential of targeting CD131, a shared receptor subunit for IL-3, IL-5 and GM-CSF, in ACO development and in preventing acute viral exacerbations.
View Article and Find Full Text PDFInfluenza Other Respir Viruses
January 2025
Department of Pediatrics, Fukushima Medical University, Fukushima, Japan.
Background: Nonpharmaceutical interventions for coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, during the pandemic altered the epidemiology of respiratory viruses. This study aimed to determine the changes in respiratory viruses among children hospitalized from 2018 to 2023.
Methods: Nasopharyngeal specimens were collected from children aged under 15 years with fever and/or respiratory symptoms admitted to a medical institution in Fukushima Prefecture between January 2018 and December 2023.
Sci Rep
January 2025
Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, 399 Wanyuan Rd, Minhang District, Shanghai, 201102, China.
China has adhered to policies of zero-COVID for almost three years since the outbreak of COVID-19, which has remarkably affected the circulation of respiratory pathogens. However, China has begun to end the zero-COVID policies in late 2022. Here, we reported a resurgence of common respiratory viruses and Mycoplasma pneumoniae with unique epidemiological characteristics among children after ending the zero-COVID policy in Shanghai, China, 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!